ABSTRACT
Purpose Evaluating the efficacy of an opioid antagonist, naloxone (NLX), to reduce the severity of post-ictal hypoxemia and immobility after focal to bilateral tonic-clonic seizures (FBTCS).
Methods ENALEPSY is a double-blind placebo (PCB)-controlled trial conducted in patients with focal epilepsy undergoing long-term video-EEG monitoring (LTM). Patient with a FBTCS during LTM were randomized 1:1 to receive intravenous NLX or PCB within the 2 minutes following the end of FBTCS. After database lock, a discrepancy between the allocated arm and the received treatment was detected, resulting in a 4:1 NLX:PCB ratio. To further explore the efficacy of NLX, we used historical control (HC) data collected in patients included in the REPO2MSE study whose characteristics matched those of patients randomized in ENALEPSY. Efficacy of NLX was then assessed versus PCB and versus HC. The primary endpoint was the delay between the end of the seizure and recovery of SpO2 ≥ 90%. Secondary efficacy outcomes included desaturation nadir and duration of the postictal immobility.
Results 33 patients contributed to the NLX group, 7 to the PCB group and 43 to the HC group. The proportion of FBTCS type 1 or 3 was 84% in NLX, 100% in PCB and 84% in HC. NLX did not improve the delay of recovery of SpO2 ≥ 90% or the desaturation nadir. In contrast, duration of the postictal immobility differed across groups. The time to mobility recovery within the first 5 minutes post-ictal was very similar in PCB (200.3±215.8 seconds) and HC (194.4±192.0 second) groups, and significantly shorter in the NLX group (128.9±151.1 seconds) when compared to HC (Hazard Ratio, 1.84; 95% CI, 1.11 to 3.05; p=0.021).
Conclusion NLX did not prevent postictal respiratory dysfunction but might reduce the duration of postictal immobility. Confirmation of this effect and its impact on SUDEP risk will require additional studies
– ENALEPSY trial evaluated the efficacy of intravenous naloxone to reduce the severity of post-ictal complications after focal to bilateral tonic-clonic seizures.
– Naloxone did not improve the delay of recovery of SpO2 ≥ 90% or the desaturation nadir
– The time to mobility recovery was significantly shorter in the NLX group when compared to historical control
– Impact of these results on SUDEP prevention will require additional studies
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02332447
Funding Statement
The ENALEPSY study was funded by the French Ministry of Health (PHRC National 2013). The REPO2MSE study was funded by the French Ministry of Health (PHRC National 2009). Vincent Rossero is funded by ERANET-NEURON – Agence Nationale de la Recherche, Grant/ Award Number: ANR-21-NEU2-0006 Sylvain Rheims is funded by HORIZON-ERC-Award Number: ERC-2023-COG-101125118
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both ENALEPSY and REPOMSE were approved by ethics committee (CPP Sud Est II 2014-853 and CPP Sud Est II 2010-006-AM6) and competent authority (ANSM 141241A-31 and ANSM B100108-40) and all patients gave written informed consent. ENALEPSY was registered with ClinicalTrials.gov (NCT02332447) on 2015-01-05.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The statistical analyses were conducted by Fatima Chorfa, Catherine Mercier and Pr Pascal Roy, Department of Biostatistics.
Trial registration: ClinicalTrials.gov NCT02332447; EudraCT 2014-003003-30
Funding: The ENALEPSY study was funded by the French Ministry of Health (PHRC National 2013). The REPO2MSE study was funded by the French Ministry of Health (PHRC National 2009). Vincent Rossero is funded by ERANET-NEURON – Agence Nationale de la Recherche, Grant/ Award Number: ANR-21-NEU2-0006
Sylvain Rheims is funded by HORIZON-ERC-Award Number: ERC-2023-COG-101125118
Data Availability
All data produced in the present study are available upon reasonable request to the authors
